Key clinical point: Tisagenlecleucel has the potential to be cost effective for B-cell acute lymphoblastic leukemia in children.
Major finding: The incremental cost-effectiveness ratio for tisagenlecleucel versus clofarabine ranged from $37,000 to $78,000 per quality-adjusted life year gained.
Study details: A cost-effectiveness analysis comparing tisagenlecleucel with clofarabine monotherapy.
Disclosures: The study was funded by the Institute for Clinical and Economic Review, which receives some funding from the pharmaceutical industry. Four authors are employees of the Institute for Clinical and Economic Review.
Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530